Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease

NCT03818685 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

95

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Triple Negative Breast Neoplasms

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Capecitabine

Sponsor

Centre Leon Berard